A vs. ARGX: Agilent vs. argenx Stock Comparison
How do Agilent (A) and argenx (ARGX) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Agilent (A) and argenx (ARGX) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but A is classified in Life Sciences Tools & Services while ARGX is classified in Biotechnology.
Agilent (A) trades as ordinary local shares, while argenx (ARGX) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.
| Profile Item | A | ARGX |
|---|---|---|
| Name | AgileThought, Inc. Class A Common Stock | argenx SE American Depositary Receipt |
| Country/Region | United States | Netherlands |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Life Sciences Tools & Services | Biotechnology |
| GICS Sub-Industry | Life Sciences Tools & Services | Biotechnology |
| Market Capitalization | 49.28 billion USD | 58.31 billion USD |
| Currency | USD | USD |
| Exchange | NYSE | Nasdaq |
| Listing Date | November 18, 1999 | May 18, 2017 |
| Security Type | Common Stock | ADR |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | A | ARGX |
|---|---|---|
| Total Return (1Y) | 22.92% | 11.91% |
| Total Return (3Y, Annualized) | 19.33% | 25.68% |
| Total Return (5Y, Annualized) | 3.03% | 24.22% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | A | ARGX |
|---|---|---|
| Volatility (1Y, Annualized) | 33.10% | 37.87% |
| Beta (5Y) | 1.22 | 0.45 |
| Max Drawdown (5Y) | -38.09% | -38.20% |
| Avg. Volume (3M) | 2.25M | 359.84K |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | A | ARGX |
|---|---|---|
| Sharpe Ratio (1Y) | 0.56 | 0.20 |
| Sortino Ratio (1Y) | 0.96 | 0.31 |
Profitability
ROE (TTM)
Capital efficiency shows on one side only: Agilent (A) earns 20.97% on shareholders’ equity, ranked against its industry; argenx (ARGX) has no ROE this period.
A
Pharmaceuticals, Biotechnology & Life Sciences industry group
20.97%
- Max
- 109.18%
- A
- 20.97%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
ARGX
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 109.18%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
- ARGX
- --
Net Margin (TTM)
Both Agilent (A) at 19.53% and argenx (ARGX) at 31.73% keep an unusually large share of revenue as bottom-line profit — each net margin clears its industry’s benchmark range.
A
Pharmaceuticals, Biotechnology & Life Sciences industry group
19.53%
- A
- 19.53%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
ARGX
Pharmaceuticals, Biotechnology & Life Sciences industry group
31.73%
- ARGX
- 31.73%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Both Agilent (A) at 25.56% and argenx (ARGX) at 36.27% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.
A
Pharmaceuticals, Biotechnology & Life Sciences industry group
25.56%
- Max
- 83.12%
- A
- 25.56%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
ARGX
Pharmaceuticals, Biotechnology & Life Sciences industry group
36.27%
- Max
- 83.12%
- ARGX
- 36.27%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | A | ARGX |
|---|---|---|
| ROE (TTM) | 20.97% | -- |
| ROA (TTM) | 8.63% | -- |
| Net Margin (TTM) | 19.53% | 31.73% |
| Operating Margin (TTM) | 25.56% | 36.27% |
| Gross Margin (TTM) | 53.65% | 59.84% |
Growth
Revenue Growth
argenx (ARGX) at 89.64% sits in the top revenue growth quartile, while Agilent (A) at 6.73% is closer to the peer norm — faster top-line expansion for ARGX.
EPS Growth
Both Agilent (A) at 3.16% and argenx (ARGX) at 53.13% land near their industries' usual EPS growth ranges, so bottom-line momentum looks broadly in line with peers on both sides.
Growth Metrics
| Metric | A | ARGX |
|---|---|---|
| Revenue Growth (YoY) | 6.73% | 89.64% |
| Revenue Growth (3Y CAGR) | 0.48% | 116.25% |
| EPS Growth (YoY) | 3.16% | 53.13% |
| EPS Growth (3Y CAGR) | 3.02% | -- |
Financial Strength
Current Ratio (MRQ)
Short-term liquidity can only be read on one side of this pairing: Agilent (A) shows current ratio of 2.05 against its industry benchmark, while argenx (ARGX) has no reading this period.
A
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.05
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- A
- 2.05
- Min
- 0.10
ARGX
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- Min
- 0.10
- ARGX
- --
Debt / Equity (MRQ)
argenx (ARGX) at 0.01 keeps leverage in the lower industry quartile, while Agilent (A) at 0.56 runs a more typical debt-to-equity mix.
A
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.56
- Max
- 1.42
- Q3
- 0.65
- A
- 0.56
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
ARGX
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.01
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- ARGX
- 0.01
- Min
- 0.00
Financial Strength Metrics
| Metric | A | ARGX |
|---|---|---|
| Current Ratio (MRQ) | 2.05 | -- |
| Debt / Equity (MRQ) | 0.56 | 0.01 |
| Net Debt / EBITDA | 1.15 | -2.70 |
Dividends
Dividend Yield (TTM)
argenx (ARGX) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Agilent (A) reports a yield of 0.59%, ranking against industry peers normally.
A
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.59%
- A
- 0.59%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ARGX
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ARGX
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
argenx (ARGX) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Agilent (A) reports a payout of 19.98%, ranking against industry peers normally.
A
Pharmaceuticals, Biotechnology & Life Sciences industry group
19.98%
- A
- 19.98%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ARGX
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ARGX
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | A | ARGX |
|---|---|---|
| Dividend Yield (TTM) | 0.59% | 0.00% |
| Dividend Payout Ratio (TTM) | 19.98% | 0.00% |
Valuation
P/E Ratio (TTM)
Both Agilent (A) at 34.47 and argenx (ARGX) at 32.12 land around their industries’ usual P/E ratio levels — neither is getting a clear earnings-multiple discount or premium versus peers.
A
Pharmaceuticals, Biotechnology & Life Sciences industry group
34.47
- Max
- 85.34
- Q3
- 43.46
- A
- 34.47
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
ARGX
Pharmaceuticals, Biotechnology & Life Sciences industry group
32.12
- Max
- 85.34
- Q3
- 43.46
- ARGX
- 32.12
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
P/S Ratio (TTM)
On P/S ratio, both Agilent (A) at 6.68 and argenx (ARGX) at 9.86 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.
A
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.68
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- A
- 6.68
- Q1
- 3.01
- Min
- 0.01
ARGX
Pharmaceuticals, Biotechnology & Life Sciences industry group
9.86
- Max
- 58.18
- Q3
- 25.77
- ARGX
- 9.86
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
Both look rich against book: Agilent (A) at 6.69 sits in the upper P/B ratio quartile, and argenx (ARGX) at 172.23 prices even higher, above its industry range.
A
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.69
- Max
- 13.53
- A
- 6.69
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
ARGX
Pharmaceuticals, Biotechnology & Life Sciences industry group
172.23
- ARGX
- 172.23
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | A | ARGX |
|---|---|---|
| P/E Ratio (TTM) | 34.47 | 32.12 |
| P/S Ratio (TTM) | 6.68 | 9.86 |
| P/B Ratio (MRQ) | 6.69 | 172.23 |
| Free Cash Flow Yield (TTM) | 2.15% | -- |